PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25565020-0	2015	Ibrutinib inhibits BTK-driven NF-kappaB p65 activity to overcome bortezomib-resistance in multiple myeloma.	Bortezomib	65-75	Bruton tyrosine kinase	Homo sapiens	19-22	
25565020-4	2015	We identified enhanced Bruton"s tyrosine kinase (BTK) activity in bortezomib-resistant MM cells and found that inhibition of BTK, either pharmacologically with ibrutinib (0.5 muM) or via lenti-viral miRNA-targeted BTK interference, re-sensitized previously bortezomib-resistant MM cells to further bortezomib therapy at a physiologically relevant concentration (5 nM).	Bortezomib	66-76	Bruton tyrosine kinase	Homo sapiens	23-47	
25565020-4	2015	We identified enhanced Bruton"s tyrosine kinase (BTK) activity in bortezomib-resistant MM cells and found that inhibition of BTK, either pharmacologically with ibrutinib (0.5 muM) or via lenti-viral miRNA-targeted BTK interference, re-sensitized previously bortezomib-resistant MM cells to further bortezomib therapy at a physiologically relevant concentration (5 nM).	Bortezomib	66-76	Bruton tyrosine kinase	Homo sapiens	49-52	
25565020-4	2015	We identified enhanced Bruton"s tyrosine kinase (BTK) activity in bortezomib-resistant MM cells and found that inhibition of BTK, either pharmacologically with ibrutinib (0.5 muM) or via lenti-viral miRNA-targeted BTK interference, re-sensitized previously bortezomib-resistant MM cells to further bortezomib therapy at a physiologically relevant concentration (5 nM).	Bortezomib	257-267	Bruton tyrosine kinase	Homo sapiens	23-47	
25565020-4	2015	We identified enhanced Bruton"s tyrosine kinase (BTK) activity in bortezomib-resistant MM cells and found that inhibition of BTK, either pharmacologically with ibrutinib (0.5 muM) or via lenti-viral miRNA-targeted BTK interference, re-sensitized previously bortezomib-resistant MM cells to further bortezomib therapy at a physiologically relevant concentration (5 nM).	Bortezomib	257-267	Bruton tyrosine kinase	Homo sapiens	23-47	
22975686-0	2013	BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB.	Bortezomib	70-80	Bruton tyrosine kinase	Homo sapiens	0-3	
34508613-0	2021	Bortezomib enhances the anti-cancer effect of the novel Bruton"s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.	Bortezomib	0-10	Bruton tyrosine kinase	Homo sapiens	56-80	
34508613-0	2021	Bortezomib enhances the anti-cancer effect of the novel Bruton"s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.	Bortezomib	0-10	Bruton tyrosine kinase	Homo sapiens	137-140	
34508613-2	2021	This study aimed to investigate the anti-cancer effects of BGB-3111 combined with bortezomib (BTZ) against the BTK-expressing MCL.	Bortezomib	82-92	Bruton tyrosine kinase	Homo sapiens	111-114	
34508613-2	2021	This study aimed to investigate the anti-cancer effects of BGB-3111 combined with bortezomib (BTZ) against the BTK-expressing MCL.	Bortezomib	94-97	Bruton tyrosine kinase	Homo sapiens	111-114	
24156429-6	2013	It is concluded that PCI-32765 and bortezomib can synergistically inhibit the proliferation and induce apoptosis of Raji and Ramos cells, the mechanism may be associated with inhibition of Btk and NFkappaB activity, down-regulation of anti-apoptotic proteins expression, such as Bcl-xl and c-IAP1, and increase of caspase-3 expression.	Bortezomib	35-45	Bruton tyrosine kinase	Homo sapiens	189-192	
23360303-0	2013	The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.	Bortezomib	213-223	Bruton tyrosine kinase	Homo sapiens	4-26	
23360303-0	2013	The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.	Bortezomib	213-223	Bruton tyrosine kinase	Homo sapiens	28-31